• Users Online: 178
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 4  |  Issue : 2  |  Page : 166-172

Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: The potential role of metformin and sitagliptin


Department of Pharmacology, Toxicology and Medicine, College of Medicine, Almustansiriya University, Baghdad, Iraq

Correspondence Address:
Prof. Hayder Mutter Al-Kuraishy
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Almustansiriya University, P. O. Box 14132, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/bbrj.bbrj_7_20

Rights and Permissions

Objective: The objective of this study was to explore the potential effects of metformin and/or sitagliptin on the oxidative stress (OS) and antioxidant capacity in patients with type 2 diabetes mellitus (T2DM). Materials and Methods: In this cross-sectional study, 64 patients with T2DM compared with 32 healthy controls, they divided into three groups: Group A: 32 healthy controls, Group B: 33 patients with T2DM on metformin therapy, and Group C: 31 patients with T2DM on metformin plus sitagliptin therapy. Fasting blood glucose, glycated hemoglobin, fasting serum insulin, insulin resistance, lipid profile, cardiac indices, and anthropometric measurements were determined. As well, OS parameters which include total oxidant status (TOS), total antioxidant status (TAS), and OS index (OSI) were measured in patients with T2DM and healthy controls. Data analysis was done using SPSS; for significance testing, unpaired Student's t-test and analysis of variance were used. Pearson correlation was also used to detect the level of correlations. Results: Patients with T2DM have a high risk of diverse cardiometabolic changes compared with the controls (P = 0.0001). TOS was high in diabetic patients (36.89 ± 4.71 μmole/L) compared with the controls (12.74 ± 3.81 μmole/L) (P = 0.0001), TAS was low in diabetic patients (1145.89 ± 293.51 μmole/L) compared with the controls (1237.61 ± 383.74 μmole/L) (P = 0.0001), and OSI was high in diabetic patients (3.21 ± 1.99) compared with the controls (1.02 ± 0.92) (P = 0.0001). Patients with T2DM on metformin plus sitagliptin illustrated low OSI compared with T2DM on metformin monotherapy (P = 0.04). Conclusion: Metformin and/or sitagliptin attenuate T2DM-induced OS through potentiation of TAC and reduction of TOC and OSI. Therefore, a combination of metformin and sitagliptin is recommended to reduce glucolipotoxicity and related OS injury.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed50    
    Printed2    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal